Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage

被引：100

作者：

Fernandez de Larrea, Carlos ^{[1
]}

Kyle, Robert ^{[2
]}

Rosinol, Laura ^{[1
]}

Paiva, Bruno ^{[3
]}

Engelhardt, Monika ^{[4
]}

Usmani, Saad ^{[5
]}

Caers, Jo ^{[6
]}

Gonsalves, Wilson ^{[2
]}

Schjesvold, Fredrik ^{[7
]}

Merlini, Giampaolo ^{[8
]}

Lentzch, Suzanne ^{[9
]}

Ocio, Enrique ^{[10
]}

Garderet, Laurent ^{[11
]}

Moreau, Philippe ^{[12
]}

Sonneveld, Pieter ^{[13
]}

Badros, Ashraf ^{[14
]}

Gahrton, Gosta ^{[15
]}

Goldschmidt, Hartmut ^{[16
]}

Tuchman, Sascha ^{[17
]}

Einsele, Hermann ^{[18
]}

Durie, Brian ^{[19
]}

Wirk, Baldeep ^{[20
]}

Musto, Pellegrino ^{[21
]}

Hayden, Patrick ^{[22
]}

Kaiser, Martin ^{[23
]}

San Miguel, Jesus ^{[3
]}

Blade, Joan ^{[1
]}

Rajkumar, S. Vincent ^{[2
]}

Victoria Mateos, Maria ^{[10
]}

机构：

[1] Hosp Clin Barcelona, Inst Invest Biomed August Pi i Sunyer IDIBAPS, Amyloidosis & Myeloma Unit, Dept Hematol, Barcelona, Spain

[2] Mayo Clin, Div Hematol, Internal Med, Rochester, MN USA

[3] Clin Univ Navarra, Ctr Invest Med Aplicada, Inst Invest Sanitaria Navarra, Pamplona, Spain

[4] Univ Med Ctr Freiburg, Med Dept, Hematol Oncol & Stem Cell Transplantat, Freiburg, Germany

[5] Levine Canc Inst, Hemat Oncol & Blood Disorders, Charlotte, NC USA

[6] CHU Liege, Dept Hematol, Liege, Belgium

[7] Oslo Univ Hosp, Oslo Myeloma Ctr, Dept Hematol, Oslo, Norway

[8] Univ Pavia, Dept Mol Med, Pavia, Italy

[9] Columbia Univ, Dept Med, New York, NY USA

[10] IBMCC USAL CSIC, Hosp Univ Salamanca IBSAL, Dept Hematol, Salamanca, Spain

[11] Hop St Antoine, Serv Hematol & Therapie Cellulaire, Paris, France

[12] Univ Hosp Nantes, Dept Hematol, Nantes, France

[13] Erasmus MC, Dept Hematol, Zuidholland, Netherlands

[14] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA

[15] Karolinska Inst, Dept Med, Stockholm, Sweden

[16] Univ Hosp Heidelberg, Internal Med 5, Heidelberg, Germany

[17] Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27515 USA

[18] Univ Hosp Wurzburg, Dept Internal Med 2, Wurzburg, Germany

[19] Cedars Sinai 2 Med Ctr, Samuel Oschin Comprehens Canc Inst, Hematol Oncol, Los Angeles, CA USA

[20] Penn State Canc Inst, Bone Marrow Transplant Program, Hershey, PA USA

[21] Referral Canc Ctr Basilicata, IRCCS CROB, Vulture, Italy

[22] St James Hosp, Dept Haematol, Dublin, Ireland

[23] Inst Canc Res, Myeloma Mol Therapy Grp, London, England

来源：

BLOOD CANCER JOURNAL | 2021年 / 11卷 / 12期

关键词：

SMOLDERING MULTIPLE-MYELOMA; FLOW-CYTOMETRY; HIGH-RISK; SURVIVAL; BORTEZOMIB; TRANSPLANTATION; QUANTIFICATION; DEXAMETHASONE; DISORDERS; CRITERIA;

D O I：

10.1038/s41408-021-00587-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Primary plasma cell leukemia (PCL) has a consistently ominous prognosis, even after progress in the last decades. PCL deserves a prompt identification to start the most effective treatment for this ultra-high-risk disease. The aim of this position paper is to revisit the diagnosis of PCL according to the presence of circulating plasma cells in patients otherwise meeting diagnostic criteria of multiple myeloma. We could identify two retrospective series where the question about what number of circulating plasma cells in peripheral blood should be used for defining PCL. The presence of >= 5% circulating plasma cells in patients with MM had a similar adverse prognostic impact as the previously defined PCL. Therefore, PCL should be defined by the presence of 5% or more circulating plasma cells in peripheral blood smears in patients otherwise diagnosed with symptomatic multiple myeloma.

引用

页数：5

共 34 条

[11] Quantification of clonal circulating plasma cells in newly diagnosed multiple myeloma: implications for redefining high-risk myeloma
Gonsalves, W. I.
Rajkumar, S. V.
Gupta, V.
Morice, W. G.
Timm, M. M.
Singh, P. P.
Dispenzieri, A.
Buadi, F. K.
Lacy, M. Q.
Kapoor, P.
Gertz, M. A.
Kumar, S. K.
[J]. LEUKEMIA, 2014, 28 (10) : 2060 - 2065
[12] Trends in survival of patients with primary plasma cell leukemia: a population-based analysis
Gonsalves, Wilson I.
Rajkumar, S. Vincent
Go, Ronald S.
Dispenzieri, Angela
Gupta, Vinay
Singh, Preet P.
Buadi, Francis K.
Lacy, Martha Q.
Kapoor, Prashant
Dingli, David
Lust, John A.
Zeldenrust, Steven R.
Hayman, Suzanne R.
Kyle, Robert A.
Gertz, Morie A.
Kumar, Shaji K.
[J]. BLOOD, 2014, 124 (06) : 907 - 912
[13] Prognostic impact of circulating plasma cells in patients with multiple myeloma: implications for plasma cell leukemia definition
Granell, Miquel
Calvo, Xavier
Garcia-Guinon, Antoni
Escoda, Lourdes
Abella, Eugenia
Ma Martinez, Clara
Teixido, Montserrat
Teresa Gimenez, Ma
Senin, Alicia
Sanz, Patricia
Campoy, Desiree
Vicent, Ana
Arenillas, Leonor
Rosinol, Laura
Sierra, Jorge
Blade, Joan
Fernandez de Larrea, Carlos
[J]. HAEMATOLOGICA, 2017, 102 (06) : 1099 - 1104
[14] Holtzman NG, 2017, BLOOD, V130
[15] Prognostic indicators in primary plasma cell leukaemia: a multicentre retrospective study of 117 patients
Jurczyszyn, Artur
Radocha, Jakub
Davila, Julio
Fiala, Mark A.
Gozzetti, Alessandro
Grzasko, Norbert
Robak, Pawel
Hus, Iwona
Waszczuk-Gajda, Anna
Guzicka-Kazimierczak, Renata
Atilla, Erden
Mele, Giuseppe
Sawicki, Waldemar
Jayabalan, David S.
Charlinski, Grzegorz
Szabo, Agoston G.
Hajek, Roman
Delforge, Michel
Kopacz, Agnieszka
Fantl, Dorotea
Waage, Anders
Avivi, Irit
Rodzaj, Marek
Leleu, Xavier
Richez, Valentine
Knopinska-Posluszny, Wanda
Masternak, Anna
Yee, Andrew J.
Barchnicka, Agnieszka
Druzd-Sitek, Agnieszka
Guerrero-Garcia, Thomas
Liu, Jieqi
Vesole, David H.
Castillo, Jorge J.
[J]. BRITISH JOURNAL OF HAEMATOLOGY, 2018, 180 (06) : 831 - 839
[16] Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group
Katodritou, Eirini
Terpos, Evangelos
Kelaidi, Charikleia
Kotsopoulou, Maria
Delimpasi, Sossana
Kyrtsonis, Marie-Christine
Symeonidis, Argiris
Giannakoulas, Nikos
Stefanoudaki, Aikaterini
Christoulas, Dimitrios
Chatziaggelidou, Christina
Gastari, Vassiliki
Spyridis, Nikos
Verrou, Evgenia
Konstantinidou, Pavlina
Zervas, Kostas
Dimopoulos, Meletios A.
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2014, 89 (02) : 145 - 150
[17] PLASMA-CELL LEUKEMIA - REPORT ON 17 CASES
KYLE, RA
MALDONADO, JE
BAYRD, ED
[J]. ARCHIVES OF INTERNAL MEDICINE, 1974, 133 (05) : 813 - 817
[18] Kyle RA, 2003, BRIT J HAEMATOL, V121, P749
[19] Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia
Lionetti, Marta
Musto, Pellegrino
Di Martino, Maria Teresa
Fabris, Sonia
Agnelli, Luca
Todoerti, Katia
Tuana, Giacomo
Mosca, Laura
Cantafio, Maria E. Gallo
Grieco, Vitina
Bianchino, Gabriella
D'Auria, Fiorella
Statuto, Teodora
Mazzoccoli, Carmela
De Luca, Luciana
Petrucci, Maria Teresa
Offidani, Massimo
Di Raimondo, Francesco
Falcone, Antonietta
Caravita, Tommaso
Omede, Paola
Morabito, Fortunato
Tassone, Pierfrancesco
Boccadoro, Mario
Palumbo, Antonio
Neri, Antonino
[J]. CLINICAL CANCER RESEARCH, 2013, 19 (12) : 3130 - 3142
[20] Hematopoietic cell transplantation for primary plasma cell leukemia: results from the Center for International Blood and Marrow Transplant Research
Mahindra, A.
Kalaycio, M. E.
Vela-Ojeda, J.
Vesole, D. H.
Zhang, M-J
Li, P.
Berenson, J. R.
Bird, J. M.
Dispenzieri, A.
Gajewski, J. L.
Gale, R. P.
Holmberg, L.
Kumar, S.
Kyle, R. A.
Lazarus, H. M.
Lonial, S.
Mikhael, J.
Milone, G. A.
Munker, R.
Nath, R.
Saccaro, S.
To, L. Bik
Vogl, D. T.
Wirk, B.
Hari, P.
[J]. LEUKEMIA, 2012, 26 (05) : 1091 - 1097

← 1 2 3 4 →